Thermo Electron
This article was originally published in The Gray Sheet
Executive Summary
Company will repurchase up to $50 mil. of its own securities and those of its publicly held subsidiaries over the next 12 months, Thermo Electron reports May 26. Under authorization of the board of directors, the firm will "repurchase these securities when they are available at prices the company considers attractive, or to maintain the required ownership of such subsidiaries for accounting and/or tax consolidation." Thermo Electron also is allowed under previous board authorization to repurchase roughly $26 mil. of its own securities or those of its subsidiaries through January 1999
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.